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Endogenous ligand (S)-glutamate (Glu) is a major excitatory neurotransmitter in the
central nervous system (CNS), which is responsible for basal excitatory synaptic trans-
mission and many forms of synaptic plasticity. On the other hand, glutamatergic hyper-
activity may lead to neurotoxicity. In fact, excessive endogenous glutamate is implicated
in a number of acute and chronic neurodegenerative pathologies such as epilepsy, cere-
bral ischaemia and Parkinson’s diseases (1). Glutamate activates specific receptors that
belong to the classes of metabotropic receptors (mGluRs, coupled to G-protein) and
ionotropic receptors (iGluRs, ligandgated ion channel). The latter are divided into the
N-methyl-D-aspartic acid (NMDA) receptor, the kainic acid (KA) receptor and the
(R,S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid (AMPA) receptor (2, 3).
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An approach for binding affinity evaluation is suggested
and exemplified using a set of triazolo [1,5-a] quinoxa-
line for the (R,S)-2-amino-3-(3-hydroxy-5-methylisoxazol-
-4-yl)-propionic acid (AMPA) receptor. Biological activity
toward the AMPA receptor (expressed as –log IC50) was
taken as a dependent variable for building Comparative
Molecular Field Analysis (CoMFA) and Comparative
Molecular Similarity Indices Analysis (CoMSIA) models.
The resulting models show the ways of increasing the
binding affinity to the AMPA receptor as a potential tar-
get for epilepsy. The statistically significant results show
that the cross-validated r2CV value (0.766) for the CoMFA
model is greater than (0.758) for the CoMSIA model. The
non-cross validated run giving the coefficient of deter-
mination r2 values of 0.944 and 0.919 for CoMFA and
CoMSIA, respectively, provided good correlation between
the observed and computed affinities of the training set
compounds. The resulting CoMFA and CoMSIA models
indicate that steric, electrostatic, hydrophobic (lipophilic),
hydrogen bond donor and acceptor substituents play a
significant role in increasing the binding affinity and se-
lectivity of the compounds toward the AMPA receptor.
* Correspondence; e-mail address: riteshn.sharma@gmail.com
In this paper, AMPA receptor will be described as a potential target for convulsive thera-
peutic intervention. Different series of compounds with inhibitory activity toward the
AMPA receptor have been developed. Most of these inhibitors are structurally derived
from AMPA, quinoxaline, quinoxalinedione or 2,3-benzodiazepine (1, 4–9). Early studies
showed that AMPA receptor antagonists were capable of blocking seizures in rodent mod-
els of epilepsy (10, 11). In spite of their promising anticonvulsant activity in various ani-
mal model studies, no AMPA receptor inhibitors are in clinical use against epilepsy to-
day. Thus, AMPA can be considered a potential target for therapeutic prevention of epileptic
seizure (8, 12). Hence, we have the proposed an approach for increasing the binding affinity
of ligands toward AMPA receptor that may help in the treatment of convulsive disorders.
Comparative molecular field analysis (CoMFA) (13) and comparative molecular si-
milarity indices analysis (CoMSIA) (14) are widely used tools for predicting biological
activity of ligands. They enable designing novel ligands with enhanced affinity to a gi-
ven receptor. To study the binding affinity, a set of triazolo [1,5-a] quinoxaline with bio-
logical activities expressed as IC50, i.e., the concentration necessary for 50% AMPA recep-
tor inhibition, was taken as a dependent variable for building CoMFA and CoMSIA models.
The resulting model would directly suggest the ways of increasing the binding affinity for
AMPA receptor.
EXPERIMENTAL
Dataset for the study
Reported in vitro AMPA receptor inhibition data on a series of triazolo [1,5-a] quino-
xaline derivatives were used for this study (Table I) (15–18). The IC50 values of 35 mole-
cules were segregated into groups of 30 and 5 as a training set and a test set, respec-
tively. To achieve data homogeneity, Ki (mmol L–1) values were converted to IC50 (mmol
L–1) by the Cheng-Prusoff equation (19) and then all IC50 values were converted to pIC50.
Molecular modeling
The 3D-QSAR was performed using the SYBYL (Tripos Inc., USA) version 6.9 in-
stalled on an IBM server and Linux operating system. The most active analogue was
subjected to conformational search. The least energy conformer thus obtained as bio-
active conformation was taken as the template and the remaining molecules were built
from it. The geometry of all molecules was optimized using the tripose force field and
Powell’s conjugated gradient with the Gasteiger-Hückel charges. The minimum energy
difference of 4.19 J mol–1 was set as convergence criterion.
Alignment
CoMFA and CoMSIA studies require the coordinate of a molecule to be aligned ac-
cording to reasonable bioactive conformation. All the molecules were aligned with re-
spect to template molecule 22 by the Atom Fit method in the SYBYL (version 6.9) molec-
ular modeling software to ensure pharmacophore matching. The alignment of molecules
is shown in Fig. 1a.
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1 H NO2 Cl –0.18 –0.34 –0.56 15
2 Et 1H-imidazol-1-yl Cl –0.47 –0.42 –0.31 15
3 H 1H-imidazol-1-yl Cl –0.10 0.36 –0.01 15
4 Et 4H-1,2,4-triazol-4-yl Cl 0.04 0.26 0.04 15
5 H 4H-1,2,4-triazol-4-yl Cl 0.74 0.58 0.58 15
6 Et 4H-1,2,4-triazol-4-yl CF3 0.58 0.56 0.62 16
7 H 4H-1,2,4-triazol-4-yl CF3 0.91 0.93 1.08 16
8 Et 3-formyl-1H-pyrrol-1-yl CF3 0.32 -0.07 0.01 16
9 H 3-formyl-1H-pyrrol-1-yl CF3 0.81 0.61 0.63 16
10 Et 1H-pyrrol-1-yl CF3 –0.45 –0.20 –0.33 16
11 H 1H-pyrrol-1-yl CF3 0.44 0.38 0.34 16
12 Et 3-carboxy-1H-pyrrol-1-yl CF3 0.34 0.46 0.55 16




CF3 –1.21 –1.41 –1.12 16
15 Et 1H-imidazol-1-yl CF3 0.34 0.09 0.02 16
16 H 1H-imidazol-1-yl CF3 0.81 0.71 0.77 16
17 Et 3-formyl-1H-pyrrol-1-yl NO2 0.07 0.13 0.08 16
18 H 3-formyl-1H-pyrrol-1-yl NO2 0.63 0.68 0.88 16
19 Et 1H-pyrrol-1-yl NO2 –0.25 –0.33 0.06 16
20 H 1H-pyrrol-1-yl NO2 0.94 0.77 0.53 16
21 Et 3-carboxy-1H-pyrrol-1-yl NO2 1.05 1.09 0.88 16
22 H 3-carboxy-1H-pyrrol-1-yl NO2 1.61 1.31 1.64 16
23 Et NO2 CF3 –1.06 –0.83 –1.16 16
24 H NO2 CF3 –0.48 –0.47 –0.70 16
25 Et NH2 CF3 –0.84 –0.68 –0.75 16
26 H NH2 CF3 –0.18 –0.24 –0.12 16
27 Et NHCOCH3 NO2 –0.92 –0.97 –0.88 16










The van der Waals potential and Coulombic term representing the steric and elec-
trostatic field, respectively, was calculated using standard tripose force fields. A distance
dependent dielectric constant was used. An sp3 carbon with a charge of +1 served as a
probe atom. CoMFA field descriptors were calculated at each lattice interaction of a regu-
lar space of 2.0 ´ 10–10 m in all three dimensions within the defined region. The steric
and electrostatic fields were truncated at ± 125.6 kJ mol–1. CoMFA QSAR equations were
derived with the partial least squares (PLS) algorithm.
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29 Et NH2 NO2 –0.18 –0.21 –0.32 16
30 H NH2 NO2 0.04 0.25 0.15 16
Test set
31 H H 4H-1,2,4-triazol-4-yl –0.74 –0.71 –0.46 17
32 Et H 4H-1,2,4-triazol-4-yl –1.11 –0.41 –0.11 17
33 H 3-formyl-1H-pyrrol-1-yl Cl 0.16 0.62 0.16 17
34 Et 3-formyl-1H-pyrrol-1-yl Cl –0.38 –0.79 –0.33 17





Fig. 1. a) Alignment of triazolo[1,5-a]quinoxaline molecules; b) CoMFA STDEV*COEFF contour
maps for steric and electrostatic fields; CoMSIA STDEV*COEFF contour maps for c) steric and
electrostatic fields; d) hydrophobic, donor and acceptor fields, of AMPA model. The most active
molecule 22 is displayed in the background.
CoMSIA interaction energy
The recently reported CoMSIA method is based on molecular similarity descriptors.
CoMSIA calculates the similarity descriptors by way of a grid lattice. For a molecule j




probe k ik iq
r( ) ( ).= -åw w aexp
2
where wik is the actual value of the physicochemical property k of atom i, wprobe.k is the
property of the probe atom with pre-set charge (+1 in this case), radius (1.53 ´ 10–10 m),
and hydrophobicity of 1 and riq is the mutual distance between the probe atom at grid
point q and atom i of the molecule. In CoMSIA calculations, five physicochemical pro-
perties (steric, electrostatic, hydrophobic, hydrogen bond donor, and hydrogen bond ac-
ceptor) were determined for all molecules. The attenuation factor value was set to 0.3.
Similarity descriptors can be calculated at all grid points inside as well as outside the
molecule. This generally follows the CoMFA protocols and is evaluated by PLS analysis.
PLS analysis
Partial Least Squares analysis (PLA) was performed to obtain a 3D-QSAR model af-
ter all of the CoMFA and CoMSIA descriptors were calculated. The PLS method was used
to correlate the activity (dependent variable) with various physicochemical properties
(independent variables). The CoMFA and CoMSIA standard scaling and column filter-
ing of 0.5 were used in PLS analysis.
Cross-validations in PLS were done by the leave-one-out procedure to find out the
optimal number of components in building regression models and to check statistic sig-
nificance of the models. The leave-one-out technique provides a good way to quantita-
tively evaluate the internal predictive ability of a model by removing one compound at
a time and then building the QSAR model and calculating the activity of the compound
using the new model constructed from the remaining compounds in the data set.
The high value of the cross-validated coefficient of determination (r2CV) and the lowest
standard error of prediction resulted in optimum number of components considered for
further analysis. The optimal number of components obtained is then used to derive the fi-
nal QSAR model using all the compounds (without cross-validation). The conventional co-
efficient of determination (r2) and F value are used to measure the quality of the model.
RESULTS AND DISCUSSION
QSAR model
CoMFA and CoMSIA models were values with derivatives of triazolo [1,5-a] quin-
oxaline from inhibition values (pIC50) with respect to the AMPA receptor. Various 3D-
-QSAR (CoMFA and CoMSIA) models were generated and the best one was selected us-
ing the statistically significant parameters. Actual and predicted values obtained after
the CoMFA and CoMSIA analysis of training and test molecules are given in Table I.
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The PLS analysis for a different number of components was tried using 0.0 kJ mol–1
column filtering value for CoMFA and CoMSIA models. Based on better statistical val-
ues, the optimum number of components were selected. For the CoMFA model, the cross-
-validated coefficient of determination (r2CV) = 0.766 with five components, non cross-
-validated coefficient of determination (r2) = 0.944, F value = 80.23 and boot straped r2 =
0.953 were determined. The values of the standard error of estimate (SEE) and the pre-
dicted residual sum of squares (PRESS) obtained for CoMFA were 0.187 and 0.48, repectively.
The CoMSIA results were obtained using the same alignment and the same training
set molecules. As depicted in Table II, individual models were developed for CoMSIA
analysis taking different combinations of fields, i.e., steric-electrostatic (S-E), steric-elec-
trostatic-hydrophobic (S-E-H), steric-electrostatic-hydrogen bond donor-hydrogen bond
acceptor (S-E-D-A) and using all (S-E-D-A-H) fields. Out of these, the model having a
combination of S, E, D, A fields was slightly better than other models. However, the all-
-field model is the one providing the most descriptive information and hence was used
for the prediction of training and test set molecules. The cross-validated r2CV = 0.758
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Table II. The comparative PLS statistic results
Parameter CoMFA
CoMSIA
S,E S,E,H S,E,D,A ALL
r2CV 0.766 0.712 0.617 0.760 0.758
N 5 6 5 5 5
SEP 0.355 0.387 0.401 0.359 0.361
r2 boot strap 0.953 0.954 0.920 0.965 0.937
r2 0.944 0.920 0.855 0.920 0.919
SEE 0.187 0.227 0.299 0.222 0.223
F value 80.23 44.01 28.24 55.40 54.75
Probalityof r2 = 0 0.00 0.00 0.00 0.00 0.00
PRESS 0.48 0.62 0.53 0.59 0.67
Contribution (%)
Steric 0.545 0.311 0.200 0.096 0.066




r2CV – cross-validated coefficient of determination.
N – No. of components.
SEP – standard error of prediction.
r2 boot strap – coefficient of determination to boot strap run.
r2 – conventional coefficient of determination.
SEE – standard error of estimate.
PRESS – Predicted residual sum of square.
S – Steric field, E – Electrostatic field, H – hydrophobic field, D – hydrogen bond donor field, A – hydrogen
bond acceptor field.
with five components, non cross-validated r2 = 0.919, F value = 54.75 and boot strapped
r2 = 0.937 were obtained from the CoMSIA all-field model. The values of the standard er-
ror of estimate (SEE) and the predicted residual sum of squares (PRESS) obtained for the
CoMSIA all-field model were 0.223 and 0.67, respectively. Correlation between the pre-
dicted activity and actual activity toward the AMPA receptor obtained from the CoMFA
and CoMSIA study is illustrated in Fig. 2. The correlation coefficient, between actual ac-
tivity and predicted activity of 0.967 and 0.965 for CoMFA and CoMSIA all-field models,
respectively, explain the good predictability of both models.
The comparative study data (Table II) of CoMFA and CoMSIA models shows that
the cross-validated r2CV and non cross-validated r2 from CoMFA is slightly higher than
the CoMSIA all-field model and SEDA model. All statistical parameters, i.e., F value,
SEE, and SEP suggest that the CoMFA model is slightly better than the CoMSIA model
for prediction of training and test set molecules.
CoMFA and CoMSIA calculate the electrostatic, steric, hydrophobic, hydrogen bond
donor and acceptor properties based on the grid built around the molecules. The results
prove that steric and electrostatic contributions are apparently different for CoMFA
(0.545 and 0.455) as compared to the CoMSIA (0.066 and 0.250) model. CoMFA model
shows nearly equal significance of steric and electrostatic properties while the electro-
static contribution in the CoMSIA model is almost three fold that of the steric contribu-
tion, indicating the importance of the electrostatic field in model generation. The re-
maining fields, like hydrophobic, hydrogen bond donor and acceptor, are virtually equal
contributors in the CoMSIA models. Since CoMFA and CoMSIA models have almost equal
statistically significant parameters, either CoMFA or CoMSIA model could be used for
prediction of training and test set molecules. However, CoMSIA can be preferred to ex-
plain the importance of hydrophobic, hydrogen bond donor and acceptor properties to-
gether with stereo-electric parameters. For external validation, test molecules were se-
lected to include a variety of substituents at positions R7 and R8 and to have triazolo
[1,5-a] quinoxaline as a common molecular scaffold. Prediction of test molecules was ob-
tained from CoMFA and CoMSIA models (Table I) with predicted residual sum of
squares (PRESS) values of 0.547 and 1.298, respectively.
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Fig. 2. Correlation of predicted activity vs. actual activity toward the AMPA receptor.
Graphical interpretation of results
3D-QSAR models depict the change in binding preference occurring upon the chan-
ge in molecular fields around ligands. Compound 22 (template), the most active mole-
cule of the series, is used for the presentation of contour maps. In the case illustrated in
Fig. 1b, for CoMFA, a sterically favorable contour near the 1H-pyrrole-3-carboxylic acid
group at position 8 and a heavy electropositive favorable contour at position R7 of the
triazolo [1,5-a] quinoxaline ring were found. They suggest that modification of the car-
boxylic group, specifically on heterocyclic substituents at position 8, and addition of the
positively charged group at position R7 would increase the binding affinity for the
AMPA receptor. It is evident from the example that molecule 13 1H-pyrrole-3-carboxylic
acid substituent is more active for the AMPA receptor than molecule 9 with 1H-pyrrole-
-3-carbaldehyde substituent at R8.
For CoMSIA (Fig. 1c), the stereo-electric contours are similar to CoMFA, excluding
the small sterically unfavorable contour at the second position of quinoxaline ring. This
illustrates the significance of the carboxyl group rather than ethyl ester at the second po-
sition of quinoxalmiering for increasing the affinity. The two contour maps for bulky and
positively charged regions, respectively, are major contributors, impling the presence of
bulky electropositively charged substituents at positions 7 and 8 which might also in-
crease the binding affinity, e.g., in molecule 22. In Fig. 1d, the unfavorable hydrogen
bond donor and hydrogen bond acceptor contour maps share a major portion at R7 and
R8 of the quinoxaline ring, indicating that absence of hydrogen bond donor and acceptor
groups near R7 and R8, respectively, may be responsible for increasing the binding affin-
ity. One hydrogen bond donor favorable contour close to 1H-pyrrole-3-carboxylic acid
group at position 8 of the quinoxaline ring suggests that the hydrogen bond donor
group at this position will possibly increase the binding affinity. Favorable hydrophobic
contours on CF3 group at position 7 and the favorable hydrophobic small contour on the
pyrole ring attached to position 8 of quinoxaline scaffold recommends the presence of
the hydrophobic group or the hydrophilic group, for increasing affinity. Thus, CoMFA
and CoMSIA models suggest that by modifying the structure of ligands, particularly at
positions R7 and R8, one could gain higher affinity toward the AMPA receptor.
CONCLUSIONS
The 3D-QSAR analysis makes it possible to relate chemical structures of ligands and
their binding affinity with respect to different bio targets by using the CoMFA and CoMSIA
techniques. This provides a direct view of the factors expressed in terms of CoMFA and
CoMSIA molecular fields (electrostatic, steric, hydrophobic, hydrogen bond donor and
acceptor) affecting the binding affinity, which in turn ‘could give a reasonably good pre-
diction of binding affinity.
Finally, this analysis is helpful in suggesting some structural modifications in known
compounds for designing novel ligands, more effective as anticonvulsive agents.
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S A @ E T A K
3D-QSAR studija za afinitet vezanja na receptor za
(R,S)-2-amino-3-(3-hidroksi-5-metilizoksazol-4-il)-propansku kiselinu
RITESH N. SHARMA, HARDIK THAKAR, KAMALA K. VASU i SUBHASH C. CHATURVEDI
U radu je vrednovan afinitet vezanja serije triazolo[1,5-a]kinoksalina na receptor za
(R,S)-2-amino-3-(3-hidroksi-5-metilizoksazol-4-il)-propansku kiselinu (AMPA). Djelova-
nje na AMPA receptor (izra`eno kao log IC50) uzeta je kao zavisna varijabla u mode-
lima usporedne analize molekulskih polja (Comparative Molecular Field Analysis, CoMFA)
i usporedne analize molekulske sli~nosti (Comparative Molecular Similarity Indices Analy-
sis, CoMSIA). Ti modeli pokazuju kako pove}ati afinitet vezanja na AMPA receptor, {to
mo`e biti korisno u terapiji epilepsije. Statisti~ki zna~ajni rezultati ukazuju da je kri`no
validirana r2CV vrijednost za CoMFA model (0,766) ve}a nego za CoMSIA model (0,758).
Koeficijenti r2 za CoMFA model (0,944) i CoMSIA (0,919) ukazuju na dobru korelaciju
izme|u izra~unatih i eksperimentalno odre|anih afiniteta vezanja prou~avane serije spo-
jeva. Prema oba modela za pove}anje afiniteta vezanja i selektivnost spojeva za AMPA
receptor zna~ajna su steri~ka, elektrostatska, hidrofobna (lipofilni) svojstva, te sposob-
nost stvaranja vodikovih veza.
Klju~ne rije~i: afinitet vezanja, 3D-QSAR, CoMFA, CoMSIA, AMPA receptor
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Supporting information: Smile structures of all compounds
Molecule Smile structure
1 O=C(O)c3nc2c(=O)[nH]c1cc(Cl)c(N(=O)=O)cc1n2n3
2 CCOC(=O)c4nc3c(=O)[nH]c2cc(Cl)c(n1ccnc1)cc2n3n4
3 O=C(O)c4nc3c(=O)[nH]c2cc(Cl)c(n1ccnc1)cc2n3n4
4 CCOC(=O)c4nc3c(=O)[nH]c2cc(Cl)c(n1cnnc1)cc2n3n4
5 O=C(O)c4nc3c(=O)[nH]c2cc(Cl)c(n1cnnc1)cc2n3n4
6 CCOC(=O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1cnnc1)cc2n3n4
7 O=C(O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1cnnc1)cc2n3n4
8 CCOC(=O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1ccc(C=O)c1)cc2n3n4
9 O=Cc4ccn(c1cc2c(cc1C(F)(F)F)[nH]c(=O)c3nc(C(=O)O)nn23)c4
10 CCOC(=O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1cccc1)cc2n3n4
11 O=C(O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1cccc1)cc2n3n4
12 CCOC(=O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1ccc(C(=O)O)c1)cc2n3n4
13 O=C(O)c4ccn(c1cc2c(cc1C(F)(F)F)[nH]c(=O)c3nc(C(=O)O)nn23)c4
14 CCOC(=O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(N1C(=O)CC(C=O)C1=O)cc2n3n4
15 CCOC(=O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1ccnc1)cc2n3n4
16 O=C(O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1ccnc1)cc2n3n4
17 CCOC(=O)c4nc3c(=O)[nH]c2cc(N(=O)=O)c(n1ccc(C=O)c1)cc2n3n4
18 O=Cc4ccn(c1cc2c(cc1N(=O)=O)[nH]c(=O)c3nc(C(=O)O)nn23)c4
19 CCOC(=O)c4nc3c(=O)[nH]c2cc(N(=O)=O)c(n1cccc1)cc2n3n4
20 O=C(O)c4nc3c(=O)[nH]c2cc(N(=O)=O)c(n1cccc1)cc2n3n4
21 CCOC(=O)c4nc3c(=O)[nH]c2cc(N(=O)=O)c(n1ccc(C(=O)O)c1)cc2n3n4
22 O=C(O)c4ccn(c1cc2c(cc1N(=O)=O)[nH]c(=O)c3nc(C(=O)O)nn23)c4
23 CCOC(=O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1ccc(N(=O)=O)c1)cc2n3n4
24 O=C(O)c4nc3c(=O)[nH]c2cc(C(F)(F)F)c(n1ccc(N(=O)=O)c1)cc2n3n4
25 CCOC(=O)c3nc2c(=O)[nH]c1cc(C(F)(F)F)c(N)cc1n2n3
26 Nc4ccn(c1cc2c(cc1C(F)(F)F)[nH]c(=O)c3nc(C(=O)O)nn23)c4
27 CCOC(=O)c3nc2c(=O)[nH]c1cc(N(=O)=O)c(NC(C)=O)cc1n2n3
28 CC(=O)Nc1cc2c(cc1N(=O)=O)[nH]c(=O)c3nc(C(=O)O)nn23
29 CCOC(=O)c3nc2c(=O)[nH]c1cc(N(=O)=O)c(N)cc1n2n3
30 Nc1cc2c(cc1N(=O)=O)[nH]c(=O)c3nc(C(=O)O)nn23
31 O=C(O)c4nc3c(=O)[nH]c2cc(n1cnnc1)ccc2n3n4
32 CCOC(=O)c4nc3c(=O)[nH]c2cc(n1cnnc1)ccc2n3n4
33 CCOC(=O)c4nc3c(=O)[nH]c2cc(Cl)c(n1ccc(C=O)c1)cc2n3n4
34 Cc4ccn(c1cc2c(cc1Cl)[nH]c(=O)c3nc(C(=O)O)nn23)c4
